Amgen's biosimilar version of Roche’s top selling cancer drug, Avastin has been approved in the US, making it the first ever cancer biosimilar approved by the FDA.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
